Loading...
XSHE
002603
Market cap3.74bUSD
Jul 10, Last price  
15.51CNY
1D
2.11%
1Q
-7.35%
Jan 2017
26.00%
IPO
19.58%
Name

Shijiazhuang Yiling Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002603 chart
P/E
20.14
P/S
3.31
EPS
0.77
Div Yield, %
1.97%
Shrs. gr., 5y
Rev. gr., 5y
-2.27%
Revenues
7.83b
+20.24%
938,555,9531,632,330,9861,649,320,0721,953,211,4301,648,676,3442,490,161,5322,921,157,2563,184,752,3683,849,587,5854,081,266,6544,814,557,8215,825,294,4988,782,479,67610,116,793,93712,532,841,02710,318,312,8506,512,734,4717,830,737,438
Net income
1.29b
P
122,117,123297,182,764315,559,119454,071,087185,806,394244,291,466354,495,209430,491,015532,686,061540,705,105599,221,881606,501,0711,218,737,6831,343,856,0142,362,756,4861,352,379,247-724,515,5811,286,478,662
CFO
1.78b
+190.75%
210,177,689318,211,329299,717,830-408,486,08570,128,56955,322,427105,904,047131,877,728641,446,959114,652,88772,366,62968,925,4491,586,172,733528,693,7143,487,736,416155,457,433611,013,1711,776,508,378
Dividend
Oct 22, 20250.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
IPO date
Jul 28, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT